Agenus Inc. Shareholders Equity (Total)

Shareholders Equity (Total) of AGEN for past 10 years: annual, quarterly and twelve month trailing (TTM) including Shareholders Equity (Total) growth rates and interactive chart. Shareholder equity, also referred to as shareholders' equity and stockholders' equity, it a corporation's owners' residual claim after debts have been paid. Equity is equal to a firm's total assets minus its total liabilities. It is found on a company's balance sheet and it's the total equity available to common shareholders (after accounting for preferred equity). Also called book value or net book value.

Highlights and Quick Summary

  • Shareholders Equity (Total) for the quarter ending June 29, 2020 was $-226 Million (a 11.59% increase compared to previous quarter)
  • Year-over-year quarterly Shareholders Equity (Total) increased by 10.3%
  • Annual Shareholders Equity (Total) for 2019 was $-231 Million (a 32.54% increase from previous year)
  • Annual Shareholders Equity (Total) for 2018 was $-175 Million (a 130.22% increase from previous year)
  • Annual Shareholders Equity (Total) for 2017 was $-75.8 Million (a 93.77% increase from previous year)
Visit for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Shareholders Equity (Total) of Agenus Inc.

Most recent Shareholders Equity (Total)of AGEN including historical data for past 10 years.

Interactive Chart of Shareholders Equity (Total) of Agenus Inc.

Agenus Inc. Shareholders Equity (Total) for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 $-225.96 $-202.5
2019 $-231.34 $-204.87 $-161.61 $-119.28 $-231.34
2018 $-174.55 $-131.39 $-113.09 $-113.23 $-174.55
2017 $-75.82 $-51.59 $-17.48 $8.9 $-75.82
2016 $-39.13 $-21.04 $16.88 $44.45 $-39.13
2015 $70.73 $76.98 $87.19 $46.26 $70.73
2014 $23.02 $48.87 $57.63 $63.29 $23.02
2013 $-4.48 $-2.88 $-17.26 $-22.68 $-4.48
2012 $-17.6 $-13.16 $-11.36 $-10.63 $-17.6
2011 $-20.83 $-16.07 $-17.15 $-12.46 $-20.83
2010 $-14.71 $-25.08 $-19.74 $-24.41 $-14.71
2009 $-16.98 $-18.91 $-16.98

Business Profile of Agenus Inc.

Sector: Medical
Industry: Drugs
Agenus Inc., a clinical-stage immuno-oncology company, discovers, manufactures, and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs, including Prophage vaccine candidate; AutoSynVax, a synthetic neo-antigen; PhosPhoSynVax, a vaccine candidate designed to induce immunity against a class of tumor specific neo-epitopes; and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops CTLA-4 and PD-1 antagonists which is in clinical trial phase I for the dose escalation study; AGEN2373, an anti-CD137 monospecific antibody which is in Phase 1 clinical trial; AGEN1223, a novel bispecific antibody designed to deplete regulatory T cells which is in a Phase 1 clinical trial; GS-1423, a tumor microenvironment conditioning anti-CD73/TGFß TRAP bi-functional antibody which is in Phase 1 clinical trial; and TIGIT antibodies. In addition, it engages in the development of INCAGN1876, an anti-GITR monospecific antibody; INCAGN1949, an anti-OX40 monospecific antibody; INCAGN2390, an anti-TIM-3 monospecific antibody; INCAGN2385, an anti-LAG-3 monospecific antibody; and MK-4830, a monospecific antibody targeting ILT4. Agenus Inc. has collaboration agreements with Incyte Corporation, Merck Sharpe & Dohme, and Recepta Biopharma SA.; and collaboration with Gilead Sciences, Inc. to develop immuno-oncology therapies. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.